DeutschNewstral
Article
Financial Times on 2024-04-17 15:18
Eli Lilly & Co: Eli Lilly weight-loss drug found to address sleep apnoea in trial
Related news
Sleep apnea reduced in people who took weight-loss drug, Eli Lilly reportsThe New York Times- Eli Lilly & Co: Eli Lilly to invest extra $5.3bn in manufacturing site for weight loss drugsFinancial Times
- FEli Lilly & Co: Eli Lilly lifts outlook on bumper sales of diabetes and weight loss drugsft.com
- Eli Lilly & Co: Eli Lilly to seek obesity drug approval that could disrupt weight loss marketFinancial Times
- FEli Lilly & Co: Eli Lilly launches cut-price version of blockbuster weight-loss drugft.com
Diabetes, weight drugs earn Eli Lilly $4B in 2QArkansas Online
Eli Lilly weight loss drug Zepbound approved by the FDANew York Post- DEli Lilly slumps after disappointing Zepbound weight-loss-drug trialdcourier.com
- MEli Lilly weight reduction drug tirzepatide knowledge launchedmvtelegraph.com
- FEli Lilly & Co: Eli Lilly races to boost capacity for rival to Novo Nordisk weight-loss drugft.com
- FEli Lilly lifts guidance on strong sales of diabetes and weight loss drugsft.com
- MEli Lilly expects FDA name on Zepbound for sleep apnea in close to time periodmvtelegraph.com
- TEli Lilly leaps as weight-loss-drug sales drive earnings and 2024 outlookthestreet.com
- IEli Lilly secures weight loss drug approval in China: How do rivals stack up?invezz.com
- MEli Lilly CEO on slicing tips, potential weight problems drug, Alzheimer’s trialmvtelegraph.com
- IEli Lilly in ‘good dialogue’ with Germany on weight-loss drug coverageinvezz.com
- MEli Lilly weight reduction drug cuts threat of creating diabetes in trialmvtelegraph.com
Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024Seattle Times